Skill Indicators Sample Clauses

Skill Indicators. An employee is required to demonstrate some of the following in the performance of his or her work:
AutoNDA by SimpleDocs
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • an ability to organise, practise and complete nursing functions in stable situations with limited direct supervision; • observation and assessment skills to recognise and report deviations from stable conditions; • flexibility in the capacity to undertake work across the broad range of nursing activity and/or competency in a specialised area of practice; and/or • communication and interpersonal skills to assist in meeting psycho-social needs of individuals/groups.
Skill Indicators. The employee has limited or no practical experience of current situations; and • The employee exercises limited discretionary judgment, not yet developed by practical experience.
Skill Indicators. The employee has limited or no practical experience of current situations; and • The employee exercises limited discretionary judgment, not yet developed by practical experience. Enrolled Nurse—pay point 2 Pay Point 2 refers to the pay point to which an Enrolled Nurse has progressed or has been appointed.
Skill Indicators.  The employee has limited or no practical experience of current situations; and  The employee exercises limited discretionary judgment, not yet developed by practical experience. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE – PAY POINT 2
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • a developing ability to recognise changes required in nursing activity and in consultation with the RN, implement and record such changes, as necessary; • an ability to relate theoretical concepts to practice; and/or • requiring assistance in complex situations and in determining priorities. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE PAY POINT 3
Skill Indicators. The employee is required to demonstrate some of the following in the performance of their work: • an ability to organise, practise and complete nursing functions in stable situations with limited direct supervision; • observation and assessment skills to recognise and report deviations from stable conditions; • flexibility in the capacity to undertake work across the broad range of nursing activity and/or competency in a specialised area of practice; and/or • communication and interpersonal skills to assist in meeting psycho-social needs of individuals/groups. Progression to the next Pay Point: shall be annually or after the completion of 1762.5 hours for an employee who is not a full time employee, subject to satisfactorily demonstrating all skills and capabilities required at this level. ENROLLED NURSE – PAY POINT 4
AutoNDA by SimpleDocs

Related to Skill Indicators

  • Performance Indicators The HSP’s delivery of the Services will be measured by the following Indicators, Targets and where applicable Performance Standards. In the following table: n/a meanç ‘not-appIicabIe’, that there iç no defined Performance Standard for the indicator for the applicable year. tbd means a Target, and a Performance Standard, if applicable, will be determined during the applicable year. INDICATOR CATEGORY INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator 2019/20 PERFORMANCE TARGET STANDARD Organizational Health and Financial Indicators Debt Service Coverage Ratio (P) 1 c1 Total Margin (P) 0 cO Coordination and Access Indicators Percent Resident Days – Long Stay (E) n/a n/a Wait Time from LHIN Determination of Eligibility to LTC Home Response (M) n/a n/a Long-Term Care Home Refusal Rate (E) n/a n/a SCHEDULE D — PERFORMANCE 2/3 INDICATOR CATEGORY Quality and Resident Safety Indicators INDICATOR P = Performance Indicator E = Explanatory Indicator M = Monitoring Indicator Percentage of Residents Who Fell in the Last 30 days (M) 2019/20 PERFORMANCE TARGET STANDARD n/a n/a Percentage of Residents Whose Pressure Ulcer Worsened (M) n/a n/a Percentage of Residents on Antipsychotics Without a Diagnosis of Psychosis (M) n/a n/a Percentage of Residents in Daily Physical Restraints (M) n/a n/a SCHEDULE D — PERFORMANCE 2.0 LHIN-Specific Performance Obligations 3/3

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Indicators Debt to Asset Ratio (10%) •Cash Flow (10%) •Total Margin (25%) Risk Assessment Results

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

Time is Money Join Law Insider Premium to draft better contracts faster.